Orly Eizenberg

1 ta ish

Sheba Medical Center

1. Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML <i>In Vitro</i> and <i>In Vivo</i>

   Katia Beider, Merav Darash‐Yahana, Orly Blaier +8

   Maqola20142 iqtibos

   ABIABI:AkademIndex/2026.other.072098